year
sinc
acut
respiratori
distress
syndrom
ard
first
describ
substanti
progress
made
identifi
risk
factor
pathogen
contributor
syndrom
characteris
protein
express
pattern
plasma
bronchoalveolar
lavag
fluid
patient
ard
despit
effort
howev
pharmacolog
option
ard
remain
scarc
frequent
cite
reason
absenc
specif
drug
therapi
includ
heterogen
patient
ard
potenti
differenti
respons
drug
possibl
wrong
target
studi
advanc
appli
biomolecular
technolog
bioinformat
enabl
breakthrough
complex
trait
cardiovascular
diseas
asthma
particularli
precis
medicin
paradigm
wherein
biomark
gene
express
pattern
indic
patient
likelihood
respond
treatment
pursu
review
consid
biolog
analyt
techniqu
could
facilit
precis
medicin
approach
ard
would
like
thank
edward
cantu
iii
year
sinc
ashbaugh
colleagu
first
describ
acut
respiratori
distress
syndrom
ard
substanti
progress
made
identifi
pathogen
contributor
syndrom
improv
ventilatori
support
patient
con
current
improv
manag
sepsi
common
precipit
ard
ventil
liber
sedat
practic
prevent
therapi
also
contribut
improv
surviv
patient
ard
nonetheless
observ
studi
across
world
mortal
patient
ard
remain
high
one
three
patient
diagnos
ard
surviv
day
pharmacolog
treatment
ard
remain
scarc
one
drug
cisatracurium
besil
show
potenti
albeit
probabl
nonspecif
benefit
randomis
trial
patient
need
new
therapi
ard
indisput
yet
numer
well
conceiv
studi
unabl
identifi
effect
treatment
drug
might
ineffect
respons
toxic
effect
therapi
nonuniform
problem
drug
time
durat
deliveri
incomplet
understand
pathogenesi
heterogen
ard
precis
approach
wherebi
therapi
specif
target
patient
like
benefit
might
overcom
limit
broadli
advoc
ard
review
consid
tool
approach
might
facilit
identif
novel
potenti
precis
therapi
ard
identifi
mechan
therapeut
relev
specif
biolog
pathway
identifi
subgroup
patient
like
respond
particular
therapi
base
biolog
perhap
ideal
substanti
inflamm
alveolar
plasma
compart
recognis
characterist
patient
ard
sinc
high
concentr
inflammatori
cytokin
associ
injuri
ventil
strategi
wors
outcom
beyond
inflam
mation
mechan
includ
endotheli
activ
respiratori
epitheli
dysfunct
sur
factant
deplet
establish
major
contributor
pathogenesi
ard
candid
studi
individu
biomark
gene
pathway
yield
continu
yield
import
associ
tabl
novel
analyt
tech
niqu
discuss
review
might
highlight
new
use
accept
marker
refin
ard
endotyp
serv
enrich
marker
futur
trial
date
howev
improv
molecular
understand
pathogen
contributor
ard
yet
translat
mortal
reduct
patient
syndrom
could
paradigmshift
breakthrough
facilit
perhap
field
ard
persist
look
light
restrict
inquiri
gene
protein
alreadi
hypoth
sise
affect
lung
injuri
effect
pharmacotherapi
acut
respiratori
distress
syndrom
ard
still
elus
clinic
biolog
heterogen
ard
suggest
precis
approach
might
help
novel
approach
understand
ard
biolog
identifi
discret
subgroup
ard
need
facilit
precis
therapi
ard
discoverybas
approach
combin
candid
marker
analys
might
help
identifi
new
pathway
relev
ard
subsequ
test
hypothesisdriven
experi
potenti
includ
novel
preclin
model
ard
new
approach
analys
complex
clinic
biolog
data
might
help
identifi
distinct
ard
subgroup
might
suitabl
target
therapi
although
continu
investig
select
candid
pathway
identifi
experiment
obser
vation
investig
ard
continu
complementari
approach
use
discoveri
method
independ
understand
pathogenesi
ard
biasfre
approach
includ
assess
largescal
variat
genom
dna
transcriptom
mrna
express
noncod
rna
protein
lipid
metabolit
compar
patient
ard
atrisk
control
gener
goal
approach
identifi
novel
candid
investig
tradit
hypothesistest
experi
figur
stress
discoveri
approach
inher
superior
hypothesisdriven
candid
investig
rather
discoveri
approach
bring
new
candid
pipelin
investig
discoveri
approach
predic
current
understand
ard
biolog
rather
investig
abil
select
repres
biospecimen
popul
patient
unaffect
control
thu
approach
free
bias
introduc
current
molecular
understand
ard
pathway
activ
molecul
incit
perpetu
lung
injuri
refer
discoveri
approach
biasfre
also
independ
known
genet
proteom
sequenc
exampl
sequenc
biasfre
wherea
wholegenom
gene
express
array
requir
knowledg
transcript
design
specif
probe
tabl
although
sceptic
might
view
discoveri
approach
akin
fish
expedit
broad
goal
studi
mere
identifi
discriminatori
marker
sampl
also
expand
consider
pathway
mechan
present
thought
contribut
diseas
explain
unexpect
marker
might
differ
significantli
case
noncas
target
tissu
tnf
gmcsf
nfkbia
tirap
darc
adipoq
ftl
gmcsf
genomewid
associ
studi
attempt
find
region
genom
genet
variat
among
unrel
case
consist
skew
compar
background
popul
extens
classic
familybas
genet
linkag
studi
genomewid
associ
studi
reli
larg
popul
detect
common
genet
variant
smalltomoder
effect
size
stipul
extrem
statist
imbal
p
valu
less
declar
signific
one
genomewid
associ
studi
trauma
associ
ard
report
singl
nucleotid
polymorph
snp
achiev
genomewid
signific
although
replic
variant
gene
warrant
mechanist
investig
identifi
first
attempt
genomewid
associ
studi
ard
instruct
highlight
insuffici
power
despit
includ
patient
ard
healthi
control
discoveri
popul
follow
addit
critic
ill
patient
replic
popul
although
genomewid
associ
studi
power
tool
reason
consensu
analyt
strategi
addit
consid
erat
might
restrict
applic
trait
ard
exampl
although
ard
caus
mani
thousand
death
year
clinic
recognit
ard
poor
valid
method
exist
diagnos
ard
electron
medic
record
code
wherea
genomewid
associ
studi
search
common
variant
involv
common
diseas
variant
confer
small
fraction
alter
risk
rarevari
analys
use
dna
sequenc
detect
polymorph
could
larg
effect
highli
uncommon
sequenc
genom
code
region
socal
exom
sequenc
done
collabor
effort
sponsor
nation
heart
lung
blood
institut
includ
case
ard
ard
case
compar
presum
healthi
control
genom
project
two
snp
gene
xk
relat
arylsulfatas
show
differenti
express
ard
case
target
amplicon
sequenc
nextgener
sequenc
also
known
metagenom
refer
candid
test
individu
known
entiti
snp
specif
transcript
protein
etc
quantifi
wherea
mediumthroughput
highthroughput
discoveri
approach
reli
known
featur
capabl
multiplex
assay
exampl
genomewid
associ
studi
cdna
microarray
reli
knowledg
genet
sequenc
gener
probe
assay
snp
transcript
contrast
biasfre
method
impli
featur
detect
might
unknownfor
exampl
nextgener
sequenc
sequenc
nucleic
acid
detect
regardless
whether
sequenc
recognis
malditofmatrixassist
laser
desorptionionis
timeofflight
cdnacomplementari
dna
mirnamicrorna
ncrnanoncod
rna
snpsinglenucleotid
polymorph
chromatinimmunoprecipit
sequenc
method
detect
sequenc
area
genom
protein
interact
dna
exampl
understand
transcript
factor
bind
sequenc
method
use
bisulfit
treatment
dna
uncov
dna
methyl
pattern
might
give
clue
dna
regul
cell
type
time
locat
time
review
detect
major
deleteri
genet
disrupt
shown
fraction
popul
clinic
pheno
type
explain
multipl
major
genet
variant
rather
one
potenti
multipl
variant
affect
ard
coexist
one
patient
even
relev
common
noncod
genet
variat
unrecognis
issu
might
contribut
imprecis
risk
estim
restrict
reproduc
search
new
candid
involv
patho
genesi
ard
restrict
genom
dna
discoveri
approach
exist
interrog
transcript
express
socal
transcriptom
dna
modifi
cation
socal
epigenom
protein
metabolit
microbiota
key
technolog
shift
facilit
explos
omic
field
abil
perform
highthroughput
featur
captur
identif
without
apriori
design
featur
would
sampl
case
tran
scriptom
mrna
featur
investig
field
progress
whole
genom
arraysi
microchip
coat
thousand
oligonucleotid
probe
specif
complementari
dna
cdna
sequenc
roughli
known
genesto
rna
sequenc
wherebi
cdna
occasion
rna
sequenc
use
nextgener
sequenc
technolog
main
advantag
rna
sequenc
compar
microarray
rna
sequenc
reli
probe
design
captur
cdna
variat
base
previou
knowledg
genom
instead
appli
sequenc
cdna
captur
sampl
result
rna
sequenc
investig
gain
insight
regulatori
role
noncod
rna
small
rna
speci
potenti
allel
chang
protein
sequenc
affect
express
complex
involv
isoform
determin
challeng
involv
appli
rna
sequenc
phenotyp
ard
trivial
summaris
obstacl
face
broad
field
transcriptomicsinclud
develop
bioinformat
solut
highdimension
data
analysi
qualiti
assur
achiev
consensu
signific
testingand
burden
might
uniqu
ard
burden
uniqu
ard
fundament
question
studi
design
tissu
profil
rna
sequenc
discov
new
marker
inform
ard
pathogenesi
lung
tissu
rare
avail
patient
aliv
earli
ard
alveolar
macrophag
adequ
substitut
kovach
colleagu
report
first
microarray
analysi
human
alveolar
macrophag
collect
broncho
alveolar
lavag
fluid
sampl
patient
earli
ard
day
identifi
pattern
rel
immun
toler
distinguish
ardsderiv
alveolar
macro
phage
healthi
control
although
contribut
alveolar
macrophag
lung
host
defenc
injuri
reso
lution
establish
would
seem
unwis
ignor
potenti
contribut
lungresid
neutrophil
lymphocyt
well
endotheli
epitheli
stromal
cell
lung
attempt
characteris
gene
express
wholeblood
circul
mono
nuclear
cell
also
done
ard
implic
dysregul
neutrophilexpress
gene
ferritin
heavi
chain
although
find
await
replic
highthroughput
approach
also
feasibl
analys
express
pattern
protein
small
molecul
metabolit
bodi
fluid
tissu
rather
attempt
quantifi
protein
molecul
known
ident
techniqu
first
separ
popul
unknown
protein
small
molecul
quantifi
identifi
advanc
granular
separ
protein
small
molecul
differenti
light
absorpt
activ
ie
matrixassist
laser
desorptionionis
timeofflight
malditof
mass
spectrometri
resolut
compound
ga
liquid
chromatographi
led
substanti
improv
compar
twodimension
gel
electrophoresi
addit
mass
spectrometri
nuclear
magnet
reson
spectroscopi
improv
accuraci
sensit
identif
unknown
protein
metabolit
high
dimension
proteom
analysi
bronchoalveolar
lavag
fluid
patient
ard
identifi
differenti
protein
express
ard
survivor
nonsurvivor
first
day
ard
nonsurvivor
manifest
decreas
express
protein
relat
coagul
iron
homoeostasi
immun
activ
increas
express
protein
relat
glycolysi
collagen
metabol
actin
cytoskeleton
highthroughput
proteom
screen
plasma
patient
ard
identifi
increas
express
glyco
protein
serum
amyloid
decreas
express
complement
factor
h
apolipoprotein
b
c
compar
plasma
healthi
control
howev
discoveri
proteom
lung
injuri
hamper
sever
factor
includ
complex
plasma
proteom
overwhelm
signal
highabund
plasma
protein
eg
albumin
limit
insight
gain
date
thu
recent
advanc
area
come
candid
marker
analys
inde
expect
promis
featur
identifi
discoveri
approach
replic
candid
marker
highlight
iter
exampl
figur
compel
associ
show
converg
support
multipl
line
evid
largescal
metabolom
also
done
bronchoalveolar
lavag
fluid
plasma
patient
ard
compar
healthi
control
wherea
bronchoalveolar
lavag
fluid
plasma
show
increas
express
lactat
citrat
creatin
metabolit
specif
fluid
exampl
bronchoalveolar
lavag
fluid
patient
ard
characteris
increas
express
guanosin
xanthin
hypoxanthinemetabolit
guanosin
uric
acid
metabol
pathwaysand
decreas
express
phosphati
dylcholin
phospho
lipid
constitut
pulmonari
surfact
plasma
patient
ard
characteris
metabolit
might
indic
disrupt
oxi
dant
stress
signal
glutathion
energi
homoeo
stasi
adenosin
endotheli
barrier
function
sphingomyelin
apoptosi
phosphati
dylserin
although
excit
proteom
metabolom
investig
done
small
sampl
size
n
individu
direct
translat
protein
metabolit
identif
ard
diagnosi
therapi
obviou
contrast
anoth
group
examin
metabolom
exhal
breath
condens
collect
ventil
critic
ill
patient
identifi
three
volatil
compoundsoctan
acetaldehyd
exhal
breath
condens
patient
ard
compar
ventil
control
use
train
valid
set
author
studi
show
three
metabolit
reason
diagnost
perform
di
crimin
improv
ad
lung
injuri
predict
score
compar
score
use
alon
lung
microbiom
repres
anoth
opportun
appli
cuttingedg
sequenc
techniqu
biasfre
manner
dickson
colleagu
show
mous
model
sepsi
induc
caecal
ligat
punctur
lung
microbiota
rapidli
modifi
sepsi
gutassoci
bacteria
domin
commun
day
gastrointestin
tract
upper
respiratori
tract
shown
sourc
sepsisinduc
lung
microbiom
alter
mice
sepsi
system
insult
wherea
shift
typic
lungresid
microb
gutassoci
bacteria
observ
mice
expos
intratrach
lipopolysaccharid
model
direct
lung
injuri
support
find
sequenc
bacteri
ribosom
rna
bronchoalveolar
lavag
fluid
patient
ard
identifi
gutassoci
bacteroid
speci
patient
compar
one
healthi
control
enrich
gut
bacteria
bronchoalveolar
lavag
fluid
associ
plasma
concentr
inflammatori
marker
thu
nonpulmonari
sepsisassoci
ard
transloc
bacteria
gut
lung
might
promin
role
previous
recognis
tradit
cultur
method
rel
insensit
anaerob
bacteria
whether
mech
anism
target
prevent
treat
ard
howev
remain
untest
potenti
omic
method
appli
ard
consid
sheer
volum
data
gener
potenti
stagger
wealth
biolog
data
often
coupl
extens
clinic
data
critic
care
set
analys
maximis
potenti
insight
novel
treatment
approach
ard
even
candid
marker
analys
novel
analyt
approach
might
need
maximis
insight
gain
integr
complex
molecular
clinic
data
tradit
biolog
data
human
be
ard
analys
one
two
way
identifi
biolog
phenotyp
strongli
associ
clinic
outcom
interest
often
death
idea
target
pathway
might
therebi
reduc
mortal
divid
patient
categori
base
clinic
evid
pre
suppos
characterist
compar
clinic
biolog
phenotyp
identifi
distinct
subgroup
might
respond
differ
treatment
common
approach
measur
biomark
thought
reflect
specif
biolog
pathway
test
associ
poor
outcom
typic
regressionbas
method
approach
appealingli
straightforward
intuit
least
simplest
form
requir
minim
advanc
train
statist
analysi
either
investig
reader
final
product
moreov
approach
led
substanti
advanc
understand
biolog
human
ard
past
three
decad
studi
rang
small
singlecentr
investig
secondari
analys
larg
multicentr
clinic
trial
report
associ
poor
clinic
outcom
biomark
key
pathway
lung
injuryfor
exampl
injuri
lung
epithelium
endotheliuma
well
numer
inflammatori
pathway
although
comprehens
review
studi
beyond
scope
review
sever
key
studi
cite
tabl
approach
particularli
well
suit
confirm
human
relev
biolog
pathway
identifi
laboratori
model
ard
approach
commonli
use
analys
candid
plasma
protein
genet
polymorph
although
recent
investi
gation
focus
unbias
discoveri
method
dna
rna
sequenc
metabolom
proteom
approach
also
notabl
limit
first
import
old
adag
correl
impli
causat
put
differ
biolog
marker
associ
mortal
ard
might
review
causal
driver
ard
mortal
therefor
might
good
therapeut
target
studi
associ
set
randomis
trial
incorpor
analysi
respons
biomark
question
randomli
assign
therapi
might
partial
mitig
elimin
issu
second
regressionbas
model
typic
use
type
analys
mandat
necessarili
facilit
analys
heterogen
within
ard
identifi
treatmentrespons
subgroup
altern
analyt
approach
better
suit
regress
method
particular
question
second
approach
often
appli
patient
data
search
novel
treatment
strategi
ard
divid
patient
subgroup
base
preexist
hypothes
clinic
evid
featur
compar
biolog
subgroup
exampl
decad
investig
focus
whether
direct
lung
injuri
ie
ard
result
direct
damag
lung
parenchyma
pneumonia
aspir
gastric
content
differ
indirect
lung
injuri
ie
ard
result
insult
distant
lung
parenchyma
nonpulmonari
sepsi
massiv
blood
transfus
clinic
studi
support
distinct
identifi
differ
endotheli
injuri
inflamm
patient
direct
indirect
lung
injuri
similar
type
analys
subdivid
ard
diffus
versu
focal
radio
graphic
chang
subgroup
base
clinic
risk
factor
eg
trauma
vs
sepsi
vs
similar
outcomefocus
method
approach
advantag
intuit
logic
particularli
clinician
recognis
practic
obviou
clinic
differ
subgroup
patient
differ
clinic
featur
natur
histori
howev
approach
reli
pre
exist
bias
diseas
classif
date
led
success
clinic
trial
target
specif
ard
subgroup
abil
quantifi
biolog
complex
advanc
past
sever
decad
novel
statist
method
design
disentangl
heterogen
within
complex
dataset
use
novel
statist
method
diseas
phenotyp
asthma
led
substanti
progress
toward
discoveri
diseas
endotypesthat
specif
subgroup
syndrom
distinct
pathobiolog
differenti
respons
treatment
method
use
translat
studi
critic
ill
similar
goal
clusterbas
method
encompass
variou
analyt
techniqu
share
broad
goal
identifi
group
cluster
observ
similar
characterist
type
method
hierarch
cluster
cluster
commonli
appli
genom
data
aim
identifi
cluster
patient
similar
gene
express
pattern
biolog
data
use
identifi
patient
cluster
cluster
subsequ
analys
differ
clinic
outcom
clinic
phenotyp
variabl
interest
multipl
exampl
exist
use
techniqu
asthma
help
identifi
endotyp
sever
studi
critic
care
clusterbas
method
use
identifi
subclass
paediatr
septic
shock
method
sever
advantag
includ
explicit
focu
reduc
heterogen
identifi
subgroup
intern
similar
unbias
approach
free
presupposit
facil
visual
represent
ie
classic
heat
map
anoth
advantag
use
cluster
ard
done
baselin
characterist
without
consider
outcom
howev
one
notabl
disadvantag
clusterbas
method
alway
identifi
cluster
test
specif
hypothesi
regard
number
cluster
particular
class
paramet
must
set
extern
might
prone
bia
regard
number
cluster
present
although
method
exist
estim
optim
number
cluster
data
anoth
advanc
analyt
approach
similar
cluster
analysi
often
fall
rubric
machin
learn
classif
tree
often
refer
classif
regress
tree
analysi
approach
design
identifi
unexpect
cutpoint
set
data
permit
classif
subgroup
might
readili
appar
approach
gener
branch
treelik
structur
branch
specif
cutpoint
given
variabl
end
multipl
termin
node
often
distinguish
differ
outcom
method
advantag
abl
identifi
pattern
data
would
otherwis
unappar
howev
classif
tree
also
notori
overfit
model
data
mandat
extern
valid
independ
dataset
treebas
model
use
hospit
inpati
identifi
predictor
clinic
deterior
adult
septic
shock
refin
prognost
stratif
base
plasma
biomark
ard
identifi
clinic
featur
associ
poor
outcom
tree
construct
base
associ
measur
variabl
specif
clinic
outcom
caveat
regard
outcomebas
model
also
appli
treesi
variabl
identifi
branch
tree
might
causal
relat
observ
differ
outcom
similar
cluster
base
model
treebas
model
also
requir
extern
potenti
arbitrari
decis
regard
number
branch
termin
node
although
method
resampl
crossvalid
develop
inform
decis
latent
class
analysi
approach
deriv
mixtur
model
explicitli
design
identifi
hidden
socal
latent
subgroup
within
larger
group
latent
class
analysi
wide
appli
review
psychiatr
research
import
contributor
studi
asthma
endotyp
one
major
strength
latent
class
model
test
hypothesi
certain
number
class
k
fit
data
better
one
fewer
class
k
provid
object
confirm
optim
number
class
given
dataset
ard
use
latent
class
analysi
identifi
two
distinct
subphenotyp
independ
analys
three
randomis
trial
two
sub
phenotyp
clearli
distinguish
part
basi
biomark
profil
one
sub
phenotyp
characteris
hyperinflammatori
com
pare
subphenotyp
respons
randomli
assign
posit
endexpiratori
pressur
fluidconserv
manag
strat
egi
appli
trauma
cohort
latent
class
analysi
also
identifi
distinct
subgroup
ard
distinguish
larg
time
ard
develop
also
clinic
characterist
plasma
biomark
express
one
disadvantag
latent
class
analysi
rel
larg
dataset
n
individu
typic
need
confid
fit
latent
class
model
recognis
heterogen
cardin
featur
ard
might
confound
tradit
genom
approach
altern
approach
appli
genom
tool
eg
genomewid
associ
studi
intermedi
trait
mean
context
ard
eg
plasma
biomark
express
mrna
transcript
appli
causal
infer
method
might
help
evalu
one
aspect
syndrom
exampl
candid
studi
shown
plasma
concentr
protein
secret
activ
endothelium
potenti
vascular
permeabilityto
strong
marker
ard
diagnosi
predict
prognosi
discoveri
genet
approach
also
implic
pathway
ard
risk
make
attract
candid
ard
intermedi
protein
consid
everi
biolog
process
degre
control
dna
genet
regul
plasma
protein
far
less
complex
ard
phenotyp
plasma
concentr
regul
fewer
gene
stronger
correl
genet
variat
measur
output
diseas
phenotyp
ard
thu
likelihood
find
genet
variant
explain
high
proport
varianc
plasma
concentr
greater
find
variant
explain
larg
proport
ard
risk
furthermor
quantit
trait
statist
power
dichotom
trait
statist
signific
result
might
detect
patient
rather
necessit
tradit
genomewid
associ
studi
sampl
size
far
achiev
popul
critic
ill
patient
genom
use
appli
causal
infer
methodstechniqu
borrow
econometr
social
scienc
fieldsto
infer
causal
observ
data
advantag
identifi
causal
biomark
ard
rather
marker
mere
correl
ard
modifi
causal
intermedi
like
influenc
diseas
outcom
experiment
evid
anim
vitro
model
allow
us
directli
test
whether
intermedi
direct
causal
effect
howev
would
uneth
randomli
assign
peopl
receiv
dose
potenti
injuri
marker
thu
method
infer
effect
potenti
mediatorfor
exampl
plasma
marker
bronchoalveolar
lavag
fluid
metabolit
whole
blood
transcripton
ard
risk
mortal
desir
marker
suggest
causal
role
rigor
experi
model
system
done
definit
show
causal
mediat
analysi
formal
method
explain
mechan
potenti
explanatori
variabl
influenc
outcom
via
intermedi
mediat
variabl
mani
quantit
trait
strong
genet
compon
thu
mediat
analysi
appli
associ
snp
diseas
outcom
test
whether
signific
portion
associ
mediat
chang
third
variabl
quantit
trait
intermedi
trait
biomark
transcript
metabolit
mediat
signific
portion
observ
risk
provid
good
evid
marker
might
mechanist
link
diseas
outcom
wei
colleagu
use
mediat
analysi
address
whether
chang
platelet
count
might
explain
ard
risk
mortal
first
identifi
genet
variant
strongli
influenc
baselin
platelet
count
critic
ill
assess
whether
snp
strongli
associ
platelet
count
also
associ
ard
risk
found
small
signific
portion
associ
snp
ard
mediat
indirectli
chang
baselin
platelet
count
relat
analysi
group
use
method
show
decreas
platelet
count
mediat
portion
ard
mortal
associ
genet
variant
quantit
trait
plasma
marker
also
har
instrument
variabl
analysi
wherebi
snp
strongli
associ
biomark
use
genet
predict
biomark
associ
genet
predict
biomark
outcom
assess
approach
sometim
call
mendelian
randomis
analysi
individu
consid
randomis
random
assort
ment
parent
allel
genotyp
might
express
high
low
level
biomark
mendelian
randomis
studi
provid
strong
support
causal
contribut
ldlcholesterol
risk
review
coronari
arteri
diseas
genet
variant
associ
plasma
concentr
ldlcholesterol
also
associ
coronari
arteri
diseas
concentr
ldlcholesterol
predict
genotyp
genet
predict
ldlcholesterol
associ
diseas
furthermor
dissect
genet
determin
ldlc
concentr
uncov
novel
treatment
platform
coronari
arteri
diseas
offer
attract
templat
ard
genet
research
appropri
intermedi
identifi
anoth
approach
determin
therapeut
relev
pathway
identifi
omic
method
test
novel
preclin
model
ard
although
thorough
review
human
anim
vitro
model
lung
injuri
beyond
scope
review
sever
develop
facilit
translat
bedsid
bench
back
worth
highlight
shown
figur
techniqu
interrog
candid
identifi
biasfre
method
rigor
experiment
design
case
model
treatment
also
monitor
variat
quantit
marker
physiolog
gene
express
recognis
shortcom
human
ard
research
rariti
lung
tissu
acut
ard
restrict
applic
cellspecif
transcriptom
epigenom
proteom
method
one
solut
scarciti
tissu
use
human
lung
declin
transplant
evalu
lung
deem
unsuit
transplant
poor
oxygen
visibl
injuri
poor
complianc
featur
common
ard
furthermor
better
simul
condit
vivo
human
lung
ventil
perfus
exvivo
lung
perfus
evlp
system
sever
hour
figur
allow
observ
physio
logic
measur
complianc
alveolar
fluid
clearanc
oxygen
sampl
lung
tissu
perfus
alveolar
fluid
clinic
trial
eg
done
test
whether
evlp
increas
number
suitabl
lung
transplant
maintain
optim
transplant
outcom
howev
sophist
system
also
optim
ard
preclin
model
screen
potenti
ard
therapi
advantag
safeti
human
exposur
access
human
lung
tissu
take
biopsi
sampl
tissu
use
pharmacolog
inhibitor
agonist
mechan
drug
action
investig
evlp
system
also
adapt
model
uniform
injuri
appli
bacteria
endotoxin
lung
make
adapt
model
hypothesistest
ard
prevent
therapi
anoth
potenti
therapeut
screen
method
use
microfluid
bioengin
threedimension
cell
cultur
produc
microengin
lungonachip
complet
alveolarcapillari
interfac
cyclic
stretch
mimic
breath
perfus
model
circul
figur
although
system
reli
human
cell
line
capabl
persist
long
term
cultur
thu
date
alveolar
epitheli
cell
deriv
lung
cancer
cell
line
rather
primari
human
alveolar
epitheli
cell
use
drug
induc
permeabl
pulmonari
oedema
model
system
shown
share
mani
featur
clinic
toxic
interleukin
includ
reduc
oxygen
tension
endotheli
epitheli
paracellular
gap
format
impress
model
could
use
test
whether
coadministr
prevent
agentsfor
exampl
transient
receptor
potenti
cation
channel
subfamili
v
member
channel
inhibitorcould
block
inter
leukin
permeabl
via
immuno
histochemistri
mechan
action
could
evalu
microfluid
lungonachip
could
also
adapt
studi
therapeut
applic
might
review
consid
highthroughput
method
drug
screen
evlp
reli
scarc
resourc
human
lung
addit
quantit
trait
plasma
protein
concentr
identifi
causal
signific
causal
infer
modal
endotyp
identif
drug
screen
could
proceed
secret
protein
outcom
improv
effici
although
promis
compound
would
still
need
test
small
larg
anim
model
ard
proceed
human
trial
evlp
lungona
chip
microdevic
might
help
select
agent
like
benefit
patient
final
field
genom
edit
revolutionis
past
year
elucid
famili
endonucleas
cluster
regularli
interspac
short
palindrom
repeat
crispr
crisprassoci
protein
ca
system
capabl
sitespecif
dna
cleavag
simplic
system
adapt
recognis
cleav
specif
genom
sequenc
har
gene
silenc
identifi
transcript
repressor
enhanc
even
insert
specif
point
mutat
genom
human
tissu
date
edit
use
make
mice
suscept
coronaviru
respons
middl
east
respiratori
syndrom
overcom
rel
speci
restrict
middl
east
respiratori
syndrom
coronaviru
exhibit
allow
test
potenti
vaccin
antibodi
treatment
futur
use
technolog
ard
could
interrog
function
signific
poli
morphism
gene
identifi
genom
wide
associ
studi
transcriptom
screen
provid
refut
evid
pathogen
causal
ard
biomark
potenti
allow
test
precis
paradigm
wherebi
target
treatment
could
test
differ
genet
background
age
rapid
technolog
analyt
advanc
promis
match
patient
therapi
like
help
least
like
harm
seem
attain
previou
point
histori
numer
challeng
remain
howev
particularli
identifi
new
drug
target
select
patient
like
benefit
approach
review
alreadi
identifi
plasma
biomark
could
serv
prognost
enrich
factor
marker
identifi
patient
like
experi
ard
increas
risk
die
ard
present
enrich
strategi
select
high
risk
patient
improv
power
clinic
trial
ensur
popul
suffici
outcom
analys
potenti
treatment
effect
causal
infer
method
preclin
model
ard
suggest
marker
causal
role
develop
progress
ard
marker
might
actual
identifi
biolog
endotyp
ard
endotyp
defin
marker
might
use
predict
enrich
wherebi
plasma
marker
could
inform
patient
like
respons
specif
therapi
direct
extens
one
could
imagin
clinic
trial
elig
might
predic
potenti
patient
express
specif
plasma
marker
approach
shown
highli
success
cancer
therapi
especi
use
tumour
gene
express
profil
select
target
therapi
asthma
endotyp
recognit
similarli
stimul
new
therapi
might
success
restrict
patient
predict
benefit
realis
potenti
biomarkerdriven
clinic
trial
ard
howev
thing
must
happen
first
marker
must
rapidli
avail
hospit
inpati
inform
potenti
trial
elig
contrast
cancer
biopsi
unlik
avail
ard
patient
provid
afford
wait
long
potenti
genet
result
technolog
measur
protein
biomark
elisa
real
time
technic
barrier
assay
gener
commerci
avail
microfluid
cell
separ
coupl
multiplex
colourcod
probe
might
eventu
allow
rapid
gene
express
test
bedsid
howev
technolog
wide
appli
critic
ill
second
biomarkerdriven
trial
would
requir
knowledg
perform
potenti
plasma
marker
time
natur
cours
ard
concentr
mani
marker
highli
variabl
time
third
mani
case
biomarkerdirect
trial
would
ideal
preced
test
potenti
therapi
preclin
model
ard
evlp
lungon
achip
addit
anim
model
ard
better
predict
whether
endotypedefin
marker
denot
pathway
modifi
potenti
therapi
acknowledg
even
precis
paradigm
ard
well
support
consist
find
across
endotyp
identif
genom
proteom
profil
even
experiment
design
evlp
potenti
therapi
might
improv
mortal
deleteri
effect
comorbid
condit
critic
ill
util
ard
prevent
progress
particularli
ard
develop
rapidli
well
design
studi
need
select
target
ard
prevent
therapi
clinic
trial
consider
address
comprehens
relat
review
issu
summari
precis
medicin
realist
paradigm
ard
could
begin
test
near
futur
omic
method
novel
model
lung
injuri
new
analyt
approach
improv
resolut
ard
endotyp
suggest
new
mechan
treatment
pharmacolog
breakthrough
might
closer
realis
njm
csc
contribut
literatur
search
figur
design
manuscript
draft
csc
report
grant
fund
consult
fee
glaxosmithklin
consult
fee
boehring
ingelheim
bayer
njm
receiv
grant
fund
glaxosmithklin
consult
fee
serv
advisori
board
sobi
search
pubm
incept
jan
search
term
genom
polymorph
gene
express
proteom
metabolom
microbiom
unsupervis
learn
cluster
analysi
latent
class
analysi
combin
acut
respiratori
distress
syndrom
acut
lung
injuri
search
limit
studi
human
be
return
list
articl
screen
manual
read
abstract
exclud
neonat
lung
injuri
neonat
respiratori
distress
syndrom
remain
manuscript
read
full
refer
list
review
appropri
possibl
cite
comprehens
recent
review
